Bayer on Thursday earned accelerated approval from the Food and Drug Administration for its cancer drug Aliqopa.
Aliqopa is intended to treat adults with relapsed follicular lymphoma who have received at least two previous therapies for the disease.
Follicular lymphoma is a slow-growing form of non-Hodgkin lymphoma that affects about 70,000 Americans annually.
The FDA's Accelerated Approval Program allows for the earlier approval of drugs to fill an unmet clinical need, according to the agency's website. The continued approval of Aliqopa is contingent on the results of further clinical trials Bayer must conduct to confirm the drug's efficacy.
More articles on supply chain:
Teva to sell contraceptive device business for $1.1B, divest remaining women's health assets
FDA reapproves leukemia drug 7 years after pulled from market
Supply chain inefficiencies leave $23B in potential savings on the table for hospitals